Hummingbird Bioscience, a Singapore and US-based drug developer with two cancer treatments on course to enter clinical trials, has received $25 million in an extended Series B round of funding led by the holding company of Korea’s SK Group.
The initial tranche of Hummingbird’s Series B closed at $19 million last December, led by Mirae Asset Venture Investment and GN Tech Venture Capital. Additional commitments came from existing backers...
China's Reworld has a technology that lowers barriers to entry in online game design, allowing anyone to become a creator. Joy Capital is backing the company to take user-generated content to another level
Pop Mart International Group, China’s largest fashion toy retailer, has filed for a Hong Kong IPO. Sequoia Capital China, Loyal Valley Capital and Huaxing Growth Fund are its three largest institutional backers.
PLMP Venture Capital (PLMP VC), an investor affiliated with a Singaporean financial technology firm, has launched a local exchange for small and medium-sized enterprises (SMEs) in Cambodia.
Indian venture capital player Iron Pillar Capital Management has brought in US-headquartered real estate investment firm Nitya Capital as a strategic investor.